Physician profile
Allison E Testroet
NPI 1568421873
$4,330.47
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $837 · 2021: $917 · 2022: $1,127 · 2023: $235 · 2024: $14.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.33 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.15 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.03 | 2019-2022 | |
| Abbvie INC. | $471.53 | 2021-2023 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $376.47 | 2019-2021 | |
| Allergan, INC. | $307.58 | 2019-2020 | |
| Glaxosmithkline, LLC. | $274.20 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $234.28 | 2022 | |
| Amgen INC. | $220.86 | 2019-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $209.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $142.51 | 2019-2022 | |
| Abbott Laboratories | $112.40 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $111.38 | 2019-2023 | |
| Astellas Pharma US INC | $104.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $102.47 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.23 | 2019-2024 | Xifaxan, Trulance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.40 | 2021-2022 | |
| Celgene Corporation | $59.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.54 | 2019-2021 | |
| Lilly USA, LLC | $49.87 | 2019-2023 | Emgality, Jardiance |
| Therapeuticsmd, INC. | $47.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $38.91 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.59 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $27.64 | 2020 | |
| Idorsia Pharmaceuticals US INC | $22.82 | 2022 | |
| Genentech USA, INC. | $20.19 | 2020 | |
| Kaleo, INC. | $19.99 | 2022 | |
| Pacira Therapeutics, INC. | $19.63 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.57 | 2019 | |
| Amarin Pharma, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Testroet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.